ARID1A and neoplasm: The study by Wu and colleagues demonstrated that a combination of EZH2 inhibitors, ABT263 and GSK126, was effective in inhibiting the growth of established tumours in a mouse model of ovarian clear cell carcinoma with mutations in ARID1A and PIK3CAH1047R.112